Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in randomized, blinded trials comparing olanzapine to other atypical antipsychotics for treatment of schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 2, Issue 2, 2008, Pages 136-146

  Stauffer, Virginia ^a   Karagianis, Jamie ^a   Sutton, Virginia ^b   Ascher Svanum, Haya ^a   Treuer, Tamas ^a   de Lima, Mauricio Silva ^a   Ball, Tamara ^c   Poole Hoffmann, Vicki ^a   Tohen, Mauricio ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b i3 Research   (United States)

^c i3 Statprobe   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

All cause discontinuation; Atypical antipsychotics; NNH; NNT; Number Needed to Harm; Number Needed to Treat; Olanzapine; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 48049110036     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.2.2.3     Document Type: Article

References (33)

1. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 2007;27(3):252-258.
2. Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry 2007;68(8):1163-1171.
3. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21.
4. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991;48(4):333-339.
5. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161(4):692-699.
6. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006;67(7):1114-1123.
7. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29(1):15-31.
8. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
9. Gray GE. Concise guide to evidence-based psychiatry. 1st ed. Washington (DC): American Psychiatric Publishing, Inc.; 2004. p. 67-68.
10. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318(26):1728-1733.
11. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338(20):1405-1412.
12. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med 2007;146(12):848-856.
13. Muthu V. The number needed to treat: problems describing non-significant results. Evid Based Ment Health 2003;6(3):72.
14. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610.
15. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-622.
16. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60(8):933-940.
17. Karagianis J, Rosenbluth M, Tohen M, Ascher-Svanum H, Treuer T, de Lima MS, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23(10):2551-2557.
18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
19. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A; HGGN Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006;81(1):1-15.
20. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-418.
21. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-1887.
22. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26(2):157-162.
23. Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26(5):453-461.
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-276.
25. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-449.
26. Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC; Olanzapine Relapse Prevention Study Group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Chn Psychopharmacol 2003;23(6):582-594.
27. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
28. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
29. Guy W. ECDEU assessment manual for psychopharmacology. DHEW publication, no. (ADM) 76-338. Rockville (MD): U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976. p. 534-537.
30. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-564.
31. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8.
32. Novick D, Suarez D, Ascher-Svanum H, Karagianis J, Perrin E, Haro JM, et al. Number needed to treat (NNT) for all-cause medication discontinuation in CATIE compared to the Schizophrenia Outpatients Health Outcomes (SOHO) study. Eur Psychiatry 2007;22(Suppl 1):S130.
33. Schooler NR, Tollefson GD, Tran PV, Gheuens J, Greb JA. Letter on article by Tran and Associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders." J Clin Psychopharmacol 1998;18(2):174-179